Stablecoin Development Corporation (SDEV)
| Market Cap | 42.58M +233.9% |
| Revenue (ttm) | -23.29M |
| Net Income | 483.44M +14,444.0% |
| EPS | 4.96 +144.4% |
| Shares Out | 50.62M |
| PE Ratio | 0.17 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 279,359 |
| Open | 0.8187 |
| Previous Close | 0.8360 |
| Day's Range | 0.8104 - 0.9000 |
| 52-Week Range | 0.7809 - 99.7500 |
| Beta | 0.07 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About SDEV
Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol. Its services intend to support protocol-level services, including staking, governance participation, validation, and related activities. The company was formerly known as NovaBay Pharmaceuticals, Inc. and changed its name to Stablecoin Development Corporation in April 2026. Stablecoi... [Read more]
Financial Performance
Financial StatementsNews
Stablecoin Development Registration statement: Registration filing
Stablecoin Development filed a registration statement on September 16, 2026, providing details about a securities offering with the SEC.
Stablecoin Development Registration statement: Registration filing
Stablecoin Development filed a registration statement on August 11, 2026, providing details about a securities offering with the SEC.
SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly Novabay Pharmaceuticals, Inc.) Stockholders
Abbott Cooper PLLC is investigating fiduciary duty claims for SDEV (formerly NovaBay Pharmaceuticals) holders who owned shares before August 19, 2025.
Stablecoin Development Corporation Reports Second Quarter 2026 Financial Results
Staking revenue of $2.2 million for the quarter and $4.7 million for the first half of 2026 SDEV grew its SKY position to 2.29 billion tokens (approximately 10% of total SKY supply) and eliminated al...
Stablecoin Development Quarterly report: Q2 2026
Stablecoin Development has published its Q2 2026 quarterly earnings report on July 30, 2026.
Stablecoin Development Earnings release: Q2 2026
Stablecoin Development released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly NovaBay Pharmaceuticals, Inc.) Stockholders
STAMFORD, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating potential legal claims on behalf of stockholders of Stablecoin Development Corporation (Nasdaq: SDEV) (formerly N...
Stablecoin Development Corporation Reports First Quarter 2026 Financial Results
Company Generated $22.3 Million of Operating Income and Reported $552.4 Million of GAAP Net Income, Including Significant Non-Cash Warrant-Related Gains
Stablecoin Development Quarterly report: Q1 2026
Stablecoin Development has published its Q1 2026 quarterly earnings report on May 20, 2026.
Stablecoin Development Earnings release: Q1 2026
Stablecoin Development released its Q1 2026 earnings on May 20, 2026, summarizing the period's financial results.
Stablecoin Development Corporation Begins Trading on NYSE American Under Ticker “SDEV”
Company Announces Completion of Corporate Name Change and Provides Updated SKY Holdings and Staking Metrics Company Announces Completion of Corporate Name Change and Provides Updated SKY Holdings and ...
NovaBay Pharmaceuticals Announces Name Change to Stablecoin Development Corporation, Reports Initial Staking Rewards, and Provides SKY Token Holdings Update
Following $134 million investment from R01 Fund LP, Framework Ventures, Tether Investments, S.A. de C.V., and Sky Frontier Foundation, Stablecoin Development Corporation has acquired 2.06 billion SKY...
Stablecoin Development Annual report: Q4 2025
Stablecoin Development has published its Q4 2025 annual report on March 19, 2026.
Stablecoin Development Transcript: EGM 2026
Six proposals were presented and approved, including major share issuances, amendments to the certificate of incorporation, and a new equity incentive plan. Quorum was established with over 96% voting power represented, and the meeting concluded with a Q&A session.
Stablecoin Development Proxy statement: Proxy Filing
Stablecoin Development filed a proxy statement on March 2, 2026, providing details for shareholder voting and corporate governance matters.
Stablecoin Development Proxy statement: Proxy Filing
Stablecoin Development filed a proxy statement on February 10, 2026, providing details for shareholder voting and corporate governance matters.
Stablecoin Development Proxy statement: Proxy Filing
Stablecoin Development filed a proxy statement on January 30, 2026, providing details for shareholder voting and corporate governance matters.
Stablecoin Development Registration statement: Registration Filing
Stablecoin Development filed a registration statement on November 25, 2025, providing details about a securities offering with the SEC.
Stablecoin Development Quarterly report: Q3 2025
Stablecoin Development has published its Q3 2025 quarterly earnings report on November 7, 2025.
NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards
EMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American's...
Stablecoin Development Proxy statement: Proxy Filing
Stablecoin Development filed a proxy statement on October 9, 2025, providing details for shareholder voting and corporate governance matters.
Stablecoin Development Registration statement: Registration Filing
Stablecoin Development filed a registration statement on October 3, 2025, providing details about a securities offering with the SEC.
Stablecoin Development Proxy statement: Proxy Filing
Stablecoin Development filed a proxy statement on September 23, 2025, providing details for shareholder voting and corporate governance matters.
NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting
EMERYVILLE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company”) previously announced a one-time special cash dividend of $0.80 per share for ...
Stablecoin Development Proxy statement: Proxy Filing
Stablecoin Development filed a proxy statement on September 18, 2025, providing details for shareholder voting and corporate governance matters.